FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of a cell-proliferative disorder, wherein the specified method includes the administration to a subject who needs it of a benzo[b]thiophene STING agonist; where the benzo[b]thiophene STING agonist is administered once every 3-28 days; and the benzo[b]thiophene STING agonist is selected from a group consisting of:
or their pharmaceutically acceptable salt. and
EFFECT: obtaining a method for the treatment of cancer.
8 cl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | 2019 |
|
RU2806274C2 |
METHOD FOR ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY STRENGTHENING | 2011 |
|
RU2627660C2 |
PYRROLO-PYRROLE COMPOSITIONS AS ACTIVATORS OF PYRUVATE KINASE (PKR) | 2018 |
|
RU2736217C2 |
HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2823875C1 |
3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
COMPOUNDS BOUND WITH BIR DOMAIN OF IAP | 2007 |
|
RU2446170C2 |
BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING AGONIST OR ANTAGONIST OF ADENOSINE RECEPTOR | 2000 |
|
RU2239455C2 |
METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
Authors
Dates
2022-05-12—Published
2018-07-30—Filed